AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance for Skyrizi (risankizumab) for the treatment of moderate to severe plaque psoriasis

AbbVie

6 December 2019 - In May 2019 , Skyrizi received positive reimbursement recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Institut national d'excellence en santé et en services sociaux (INESSS).

AbbVie announced an agreement was reached with the pan-Canadian Pharmaceutical Alliance (pCPA) regarding SKYRIZI™ (risankizumab) for the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.

Read AbbVie press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Market access , Canada